Abstract
Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs (P = 0.03) with a significant improvement in survival (P = 0.004).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
British Journal of Cancer Open Access 15 June 2010
-
A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)
British Journal of Cancer Open Access 06 October 2009
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fukuoka, M., Masuda, N., Negoro, S. et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 75, 306–309 (1997). https://doi.org/10.1038/bjc.1997.50
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.50
This article is cited by
-
Predictors of response of patients with solid tumors to granulocyte colony-stimulating factor
International Journal of Clinical Pharmacy (2013)
-
Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients
Breast Cancer Research and Treatment (2011)
-
A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
British Journal of Cancer (2010)
-
A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605)
British Journal of Cancer (2009)